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Abstract: A growing body of evidence suggests that activation of nuclear factor kappa B 
(NF-κB) signaling pathways is among the inflammatory mechanism involved in the 
development of insulin resistance and chronic low-grade inflammation in adipose tissues 
derived from obese animal and human subjects. Nevertheless, little is known about the roles 
of NF-κB pathways in regulating mitochondrial function of the adipose tissues. In the present 
study, we sought to investigate the direct effects of celastrol (potent NF-κB inhibitor)  
upon mitochondrial dysfunction-induced insulin resistance in 3T3-L1 adipocytes. Celastrol 
ameliorates mitochondrial dysfunction by altering mitochondrial fusion and fission in 
adipocytes. The levels of oxidative DNA damage, protein carbonylation and lipid 
peroxidation were down-regulated. Further, the morphology and quantification of intracellular 
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lipid droplets revealed the decrease of intracellular lipid accumulation with reduced lipolysis. 
Moreover, massive production of the pro-inflammatory mediators tumor necrosis factor-α 
(TNF-α) and interleukin-1β (IL-1β) were markedly depleted. Insulin-stimulated glucose 
uptake activity was restored with the enhancement of insulin signaling pathways. This study 
signified that the treatments modulated towards knockdown of NF-κB transcription factor 
may counteract these metabolic insults exacerbated in our model of synergy between 
mitochondrial dysfunction and inflammation. These results demonstrate for the first time 
that NF-κB inhibition modulates mitochondrial dysfunction induced insulin resistance in 
3T3-L1 adipocytes. 
Keywords: adipocytes; mitochondrial dysfunction; inflammation; oxidative stress;  
insulin resistance; celastrol; nuclear factor kappa B (NF-κB) 
 
1. Introduction 
In recent years, the roles of mitochondrial dysfunction-induced inflammation towards progression of 
insulin resistance, the forerunner of type 2 diabetes mellitus, have acquired important new dimensions [1–4]. 
Indeed, a number of studies have discovered that the impairments of mitochondrial functions in skeletal 
muscles, liver and adipose tissues of both human and animal disease subjects are etiologically associated 
with low-grade chronic inflammation [5,6]. In light of data indicating a pathophysiologic role of 
mitochondrial dysfunction in the occurrence of inflammation and insulin resistance, it is intriguing to 
hypothesize that the metabolic adaptations observed in these target tissues may affect the whole body 
metabolism. To a smaller extent, it is now becoming clear that the derangements of cellular inflammatory 
mediators are inextricably linked to the development of oxidative stress and reduced mitochondrial 
functions in insulin resistance state. Although the molecular details of such signaling remain enigmatic, 
several reports have suggested that mitochondrial stress leads to the intense oxidation of mitochondrial 
DNA, lipid and protein, resulting in the advancement of pro-inflammatory cytokines production in  
the tissues [1,5,7]. 
Adipose tissues are the group of heterogeneous mix of adipocytes, which constitute a wide range of 
fat tissues, immune cells, stroma-vascular cells, such as fibroblast, endothelial cells and pericytes [8]. 
The integrative roles of these tissues in controlling numerous metabolic signaling pathways are critical 
for maintaining energy homeostasis. The enlargement adipocytes mass and hyperplasia may lead to 
reduced oxygen supply with consequent hypoxia. These conditions result in an infiltration of 
macrophage, resulting in the enormous accumulation of various pro-inflammatory cytokines [9,10]. 
Increasing experimental and clinical evidences have clearly documented that adipose tissue is the most 
common sites of inflammation in the progression of obesity-related conditions [11,12]. The macrophage 
infiltration results in the immense production of reactive oxygen species (ROS) and oxidative stress, 
setting up a vicious cycle and disturbing the steady-state of body homeostatic control [7,13]. 
Augmented level of circulating cytokines, leukocyte infiltration and oxidative stress have been 
utilized as the most current model of obesity-linked adipose inflammation [11,14]. An elevation of  
non-esterified free fatty acid (FFA) level activate inflammatory signaling pathways of toll-like receptor 
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(TLR) family and inflammasome through impairment of mitochondrial function in several peripheral 
tissues [2,15–18]. Overwhelmed production of ROS drives intense oxidation of lipid, proteins and 
mitochondrial DNA (mtDNA), compromising genes encoding respiratory chain complexes as  
well as disturbing the efficiency of oxidative phosphorylation as a whole [4,19,20]. In this regard, further 
experimental analyses should focus on the investigation of inflammatory pathways in modulating 
mitochondrial functions. The IκB kinase-β (IKK-β)/nuclear factor kappa B (NF-κB) pathway has been 
implicated in the early key event in the pathogenesis of insulin resistance [6,21]. Presumably through its 
ability to regulate a wide range of pathological process in insulin resistance, NF-κB dysregulation may 
directly contributes to variety of metabolic dysfunctions observed in peripheral tissues. Notably,  
high expressions of inflammatory gene in the context of mitochondrial dysfunctions are vital in enhancing 
the sensitivity of NF-κB binding site [22]. 
Celastrol is a quinone methide triterpenoid that derived from the root of Tripterygium wilfordii 
(Thunder of God Vine). This active compound possesses several biological activities, including 
antioxidant, anti-cancer, and anti-inflammatory [23,24]. The exact molecular mechanism for mode of 
action of this compound is poorly understood with largely unknown functions, but it was shown to act 
as a potent inhibitor of NF-κB transcription factors without affecting DNA-binding activity of activator 
protein 1 (AP-1) [25]. Recently, in vivo co-administration of celastrol in diabetic mice results in the 
improvement of insulin sensitivity, glycemic control and oxidative stress with significant enhancement 
of renal functions and structural changes [26]. Nevertheless, there is no current evidence reporting the 
exact role of celastrol on adipocytes with insulin resistance. 
As mitochondrial dysfunction is strongly associated with the development of insulin resistance,  
we undertook a more focused approach at the cellular level to investigate the systematic roles of  
IKK-β/NF-κB pathways inhibition in alleviating mitochondrial dysfunction-induced insulin resistance 
in 3T3-L1 adipocytes. This study established an in vitro model of insulin resistance induced by 
oligomycin (ATP synthase inhibitor) on 3T3-L1 adipocytes. In this study, we observed the mechanistic 
effects of celastrol (NF-κB inhibitor) on the mitochondrial functions, lipolysis with intracellular lipid 
accumulation, glucose uptake activity, insulin-signal-transduction related molecules such as insulin 
receptor substrate 1 (IRS1), Akt/protein kinase B (PKB), Akt substrate of 160 kDa (AS160), glucose 
transporter 1 (GLUT1) and glucose transporter 4 (GLUT4). The levels of pro-inflammatory cytokines 
were also measured in the study, with an attempt to investigate that NF-κB pathway is the target for 
ameliorating mitochondrial dysfunction in the development of insulin resistance and type 2 diabetes. 
2. Results and Discussion 
2.1. Effect of Oligomycin and Celastrol on the Cell Viability and NF-κB Expression of 3T3-L1 Adipocytes 
We used differentiated 3T3-L1 adipocytes as an in vitro cellular model to study the ameliorative 
properties of celastrol on mitochondrial dysfunction induced by mitochondrial inhibitor oligomycin that 
can lead to insulin resistance. The viability assay was used to determine the suitable concentration  
and possible cytotoxic effects of oligomycin (Figure 1A) and celastrol (Figure 1B) treatments on fully 
differentiated 3T3-L1 adipocytes. After serum starvation, 3T3-L1 adipocytes were incubated in the 
presence of different doses of oligomycin and celastrol for 48 h. As shown in Figure 1C, both oligomycin 
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and celastrol decreased the cell viability in a dose-dependent manner. The optimal dose of  
oligomycin that did not affect the cell viability was 10 μM. The cell viability of 3T3-L1 adipocytes 
incubated with celastrol discovered that the significant decline of cell viability was exhibited at the 
concentration of 10, 20 and 30 μM by 37%, 48% and 56%, respectively. Accordingly, optimal dose of 
10 and 5 μM for oligomycin and celastrol were chosen in the assay, respectively. The time-course 
dependent was evaluated for each optimal dose (Figure 1D). The result depicted that 24 and 48 h 
treatment of both inhibitors on 3T3-L1 adipocytes did not significantly reduce the cell viability. 
Therefore, 48 h treatment of both inhibitor was chosen. Additionally, to confirm with our hypothesis on 
the involvement of NF-κB activation in the event of mitochondrial dysfunction, the protein expression 
of NF-κB level in both treated group was measured. The result showed that oligomycin significantly  
(p < 0.05) amplified NF-κB expression by 50% in the differentiated 3T3-L1 adipocytes whereas 29% 
reduction of NF-κB expression was exhibited by cells incubated with celastrol compared to control  
cells (Figure 1E). 
Figure 1. Effects of oligomycin and celastrol on cell viability. Chemical structures of  
(A) oligomycin and (B) celastrol were shown; The (C) dose-response and (D) time course 
of the cell viability for oligomycin and celastrol was determined via MTT assay. After serum 
starvation, the fully differentiated 3T3-L1 adipocytes were incubated with different doses of 
oligomycin (5, 10, 20 and 30 µg/mL) and celastrol (5, 10, 20 and 30 μM) in DMSO for 48 h. 
Time-course dependent (0, 12, 24, 36 and 48 h) was determined for each optimal dose.  
Effect of oligomycin and celastrol on nuclear factor kappa B (NF-κB) expression was 
performed via (E) immunoblotting analysis. β-actin was used as loading control. Protein 
levels measured were normalized against β-actin. Results were expressed as means ± SEM  
(n = 6–8). * p < 0.05 vs. untreated control. 
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2.2. NF-κB Inhibitor Recues 3T3-L1 Adipocytes from Oligomycin Induced Mitochondrial Dysfunction 
As shown in Figure 2A, exposure of differentiated 3T3-L1 adipocytes to oligomycin for 48 h 
significantly decreased mitochondrial intracellular ATP concentration at the basal (48%, p < 0.05) and 
insulin-stimulated condition (58%, p < 0.01) compared to untreated control. After then, we inhibited  
the activation of NF-κB using 5 µM celastrol after exposure of 3T3-L1 adipocytes to oligomycin.  
The result revealed that celastrol significantly attenuated mitochondrial dysfunction in adipocytes treated 
with oligomycin by enhancing intracellular ATP concentration in the absence (28%, p < 0.05) and 
presence of insulin (41%, p < 0.05) (Figure 2A). To explore this relationship further, measurement of 
mitochondrial membrane potential was carried out. The results showed that oligomycin markedly (70%, 
p < 0.01) lessened the mitochondrial membrane potential of the adipocytes and this reduction was 
significantly inhibited by an escalation of 61% (p < 0.05) mitochondrial membrane potential after  
co-administration with celastrol for 48 h compared to control (Figure 2B). Mitochondrial superoxide 
production was determined with a fluorescence probe Mitosox™ Red (Invitrogen Molecular Probes, 
Carlsbad, CA, USA). Treatment of 3T3-L1 adipocytes with oligomycin significantly resulted in the 
elevation of ROS production by 50% (p < 0.05) compared to untreated control but was evidently 
diminished by celastrol treatment as much as 29% (p < 0.05) (Figure 2C). 
Figure 2. Effects of celastrol on mitochondrial function of differentiated 3T3-L1 adipocytes 
with mitochondrial dysfunction was assessed via (A) intracellular ATP concentration;  
(B) mitochondrial membrane potential (MMP) and (C) mitochondrial superoxide production. 
Basal level and insulin-stimulated condition are shown. Basal rate refers to the rate of 
glucose transport in the absence of insulin. Results are expressed as means ± SEM (n = 6).  
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2.3. Effect of Celastrol on Mitochondrial Dynamics of 3T3-L1 Adipocytes with Mitochondrial Dysfunction 
Mitochondrial dynamics involving fusion and fission have been recognized as one of the key 
occasions in the mitochondrial metabolism. To study the involvement of NF-κB activation in adipocytes 
with mitochondrial dysfunction, we continued to examine the mitochondrial protein levels such as 
mitofusin 1 (Mfn1), mitofusin 2 (Mfn2), and dynamin-related protein 1 (Drp1), which are participated 
in mitochondrial dynamics process. Our data showed that oligomycin treatment lead to the significant 
declined of Mfn1 protein level by 40% in 3T3-L1 adipocyte, but was significantly re-amplified (30%,  
p < 0.05) by celastrol (Figure 3A). However, we found no significance difference on Mfn2 protein levels 
on adipocytes treated with oligomycin as well as co-treatment with celastrol (Figure 3B). Meanwhile, 
Drp1 protein level was augmented (38%, p < 0.05) in oligomycin treated cells compared to control cells 
and completely reversed by celastrol (Figure 3C). 
2.4. Effect of Celastrol on Impairment of Mitochondrial Respiratory Chain Elicited Oxidative Stress in 
3T3-L1 Adipocytes 
Oxidative stress is a key link between inflammation and insulin resistance [6]. To address this 
association, the oxidative profile of adipocytes treated with oligomycin and its co-incubation with NF-κB 
inhibitor was evaluated. Oligomycin significantly multiplied the formation of 8-hydroxydeoxyguanosine 
(8-OHdG) by 3.21-fold (p < 0.01) in 3T3-L1 adipocytes. In parallel, our data evidenced that treatment 
with the celastrol on adipocytes with mitochondrial dysfunction significantly diminished the formation of 
8-OHdG level by 1.87-fold (p < 0.01) (Figure 4A). The role of protein carbonylation in the pathogenesis 
of mitochondrial dysfunction and oxidative stress-related inflammation is well recognized [27]. Hence, 
calorimetric quantification of carbonylation of protein by-products was employed. In this study, we 
found that carbonylation of proteins was considerably (p < 0.01) elevated in oligomycin-treated cells than 
those of the control. The regulatory effect of celastrol on adipocyte with increased protein carbonylation 
was then further examined. Evaluation of protein carbonylation assay showed that co-incubation of 
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oligomycin-treated adipocytes with celastrol reduced the protein carbonylation levels by 0.8-fold  
(p < 0.05) compared to oligomycin-treated cells (Figure 4B). 
Figure 3. Effects of celastrol on mitochondrial dynamics of differentiated 3T3-L1 
adipocytes treated with oligomycin. The mitochondrial fusion/fission protein levels in 
adipocytes treated with oligomycin, celastrol and control cells were analyzed by Western 
blot with the corresponding antibodies. Representative Western blot and densitometric 
analysis of Western blot results for (A) Mfn1, (B) Mfn2, and (C) Drp1 were determined.  
β-actin was used as loading control. Protein levels measured by densitometry were 
normalized against β-actin signals. The results are similar of those obtained from three 
independent experiments. * p < 0.05 vs. untreated control; + p < 0.05 vs. oligomycin-treated 
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We then measured the lipid peroxidation of adipocytes with mitochondrial dysfunction induced by 
oligomycin treatment. The result revealed a significant upsurge of the lipid peroxidation (MDA) level 
in adipocytes treated with oligomycin compared to untreated control (270%, p < 0.01). In addition to the 
improvement of DNA oxidative damage and protein carbonylation, co-treatment with celastrol in 
oligomycin-treated cells exhibited with amelioration of lipid peroxidation level by 1.39-fold reduction 
(p < 0.01) (Figure 4C), signifying the enhancement of oxidative profile by inhibiting NF-κB activation 
may directly contribute to a significant role in rescuing adipocytes from the state of mitochondrial 
dysfunction induced by oligomycin. 
2.5. NF-κB Inhibitor Reduces Lipolysis and Alleviates Accelerated Intracellular Lpid Accumulation in 
3T3-L1 Adipocytes with Mitochondria Dysfunction 
Lipolysis is the key metabolic process via engagement of the triglycerides breakdown into three 
molecules of free fatty acids and one molecule of glycerol. To determine the effect of NF-κB inhibitor 
on lipolysis in the context of mitochondrial dysfunction of adipocytes, the quantification of the free fatty 
acid and glycerol release was measured. Treatment with oligomycin on 3T3-L1 adipocytes significantly 
intensified the release of fatty acids and glycerol from adipocytes by 0.7- (p < 0.05) and 2.36-fold  
(p < 0.01), respectively, compared to untreated cells. NF-κB inhibition by celastrol leads to the 
pronounced reduction in free fatty acids (64%, p < 0.05) and glycerol (197%, p < 0.01) release compared 
to oligomycin-treated cells, signifying the down-regulation of lipolysis in the adipocytes with mitochondrial 
dysfunction could be modulated towards knockdown of NF-κB activation (Figure 5A,B). 
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Figure 4. Effects of celastrol treatment on oligomycin-induced oxidative stress in  
3T3-L1 adipocytes. Celastrol significantly reduced the oxidative stress of adipocytes  
with mitochondrial dysfunction. Oxidative profiles of adipocytes were determined via  
(A) measurement of DNA oxidative damage (8-OHdG); (B) protein carbonylation and  
(C) lipid peroxidation (MDA). Results are expressed as means ± SEM (n = 6). ** p < 0.01 vs. 
untreated control; + p < 0.05 and ++ p < 0.01 vs. oligomycin-treated cells. 
 
 
Concomitant to lipolysis, we then focused on intracellular lipid accumulation to determine if celastrol 
has an effect on intracellular lipid deposition of 3T3-L1 adipocytes. The intracellular lipid accumulation 
in 3T3-L1 adipocytes treated with oligomycin and celastrol was assessed via Oil Red O assay 
(morphological and spectrophotometric quantification). It is worth noting that treatment of 3T3-L1 
adipocytes with oligomycin significantly boosted the intracellular lipid accumulation. As visualized 
using Oil Red O staining, the formation of numerous cytosolic lipid droplets, larger and prominent 
increase in lipid vesicles with scattered and abnormal lipid droplet distributions were observed in  
3T3-L1 adipocytes treated with oligomycin (Figure 5E) compared to the vehicle-treated cells with 
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DMSO (Figure 5C) and MDI (3-isobutyl-1-methylxanthine, dexamethasone, and insulin) induction 
media (Figure 5D). The normal differentiated cells treated with MDI were exhibited with a typical 
adipocyte phenotype with round-shaped lipid droplets. In the quantitative examination using optical 
density at 490 nm, the addition of oligomycin in differentiated 3T3-L1 adipocytes was shown to  
up regulate intracellular lipid accumulation by 67% (p < 0.05) compared with MDI-treated cells  
(Figure 5G). Importantly, we demonstrated that the metabolic inhibition of NF-κB pathways by celastrol 
significantly (p < 0.05) reduced the intracellular accumulation of lipid droplets in adipocytes with insulin 
resistance by 52% as morphologically and quantitatively shown in Figure 5F,G. 
Figure 5. Effects of celastrol treatment on lipolysis and intracellular lipid accumulation of 
differentiated 3T3-L1 adipocytes with mitochondrial dysfunction. In the presence of MDI, 
fully differentiated 3T3-L1 adipocytes were incubated with oligomycin and celastrol for 48 h 
differentiated cells were on analyzed for (A) free fatty acids and (B) glycerol release as described 
in materials and methods. The Oil Red O stained adipocytes were photographed at 40× 
magnification; (C) Untreated control (DMSO); (D) MDI-treated cells; (E) Oligomycin-treated 
cells and (F) Oligomycin + celastrol-treated cells. Figures represent one of three independent 
experiments; and (G) Quantification of intracellular lipid droplets in 3T3-L1 adipocytes treated 
with oligomycin and celastrol was performed accordingly. The results are representative of those 
obtained from three independent experiments. All values are presented as means ± SEM of 
three independent experiments. * p < 0.05 and ** p < 0.01 vs. untreated cells; + p < 0.05 and 
++ p < 0.01 vs. oligomycin-treated cells. 
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2.6. NF-κB Inhibitor Suppress Production of Tumor Necrosis Factor-α (TNF-α) and Interleukin-1β 
(IL-1β) in the Event of Mitochondrial Dysfunction of 3T3-L1 Adipocytes 
IL-1β and TNF-α are major circulating cytokines that promote inflammatory action in adipocytes.  
As shown in Figure 6A,B, treatment with oligomycin on fully differentiated 3T3-L1 adipocytes for 48 h 
significantly led to the amplification of IL-1β (4.63-fold, p < 0.01) and TNF-α (4.15-fold, p < 0.01) 
secretion from adipocytes compared to untreated control. Celastrol significantly decreased the release of 
TNF-α (2.68-fold, p < 0.05) and IL-1β (3.37-fold, p < 0.05) from adipose tissue. 
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Figure 6. Effects of celastrol treatment on differentiated 3T3-L1 adipocytes treated with 
oligomycin. The measurement of pro-inflammatory cytokine (A) interleukin-1β (IL-1β)  
and (B) tumor necrosis factor-α (TNF-α) was analyzed using a commercially available 
ELISA kit. Results were expressed as means ± SEM (n = 8). ** p < 0.01 vs. untreated control; 
+ p < 0.05 vs. oligomycin-treated cells. 
 
2.7. Co-Incubation of Celastrol Lead to the Restoration of Insulin-Induced Glucose Uptake Activity 
and Improved Insulin Signaling Cascades in Oligomycin-Treated 3T3-L1 Adipocytes 
To investigate whether NF-κB activation may play a significant role in affecting glucose metabolism 
of adipocytes with mitochondrial dysfunction, we first looked at the event of glucose uptake activity of 
3T3-L1 adipocytes with or without treatments. Cells in 24-well plates were treated for 48 h with 
oligomycin and celastrol in growth media in the presence or absence of insulin. The result showed  
insulin-induced glucose uptake was 0.24 times higher than that in normal basal group, but was reduced 
as much as 37% (p < 0.05) and 47% (p < 0.05) at the basal and insulin-stimulated condition, respectively, 
after incubation with oligomycin for 48 h. Co-treatment with celastrol partly reversed the glucose uptake 
activity of adipocytes with mitochondrial dysfunction. Insulin-induced glucose uptake was boosted by 
37% (p < 0.05) after co-incubation with 5 μM celastrol for 48 h (Figure 7A), thus partly reverting the 
cell to normal phenotype relative to untreated control. 
Given the importance of insulin signaling activity in adipose tissue, it is appealing to investigate the 
association of NF-κB pathways in the context of mitochondrial dysfunction by measuring insulin 
signaling activity and relative expression of glucose transporter protein in adipocytes. IRS1 is a protein 
effector that consists of multiple tyrosine phosphorylation motifs that mediate the metabolic growth of 
cell towards insulin stimulation. One of the important IRS1 tyrosine residues involved in the activation 
of phosphoinositide 3-kinase (PI3K) relative to insulin response is Tyr612. Akt, also known as  
protein kinase B is a serine/threonine protein kinase that regulates numerous signaling pathways 
including proliferation, survival and metabolism. Phosphorylation of serine 473 (Ser473) residues in  
the hydrophobic C-terminal regulatory domain is largely dependent on insulin stimulation. AS160 is  
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a downstream effector of Akt activation in distal insulin signaling pathways that modulate the increased 
translocation of cell-surface GLUT4 in 3T3-L1 adipocytes. In the present study, we showed that  
the phosphorylation of IRS1, Akt and AS160 under insulin stimulation was completely lessened after 
incubated with oligomycin for 48 h. Meanwhile, co-treatment with celastrol under insulin stimulation 
significantly attenuated detrimental effect regulated by oligomycin through an elevated phosphorylation  
of these residue proteins (Figure 7B–D). Additionally, the expression of GLUT 4 was down-regulated 
while GLUT1 protein level was unaltered in adipocytes treated with oligomycin. Co-treatment  
of celastrol on adipocytes with mitochondrial dysfunction restored the level of GLUT 4 compared  
to control (Figure 7E). 
Figure 7. Effects of celastrol treatment on insulin signaling cascades and glucose transporter 
in differentiated 3T3-L1 adipocytes with mitochondrial dysfunction. Representative Western 
blot of insulin signaling activity for (A) glucose uptake; (B) Tyr612 phosphorylation of 
IRS1; (C) Ser473 phosphorylation of Akt; (D) Thr642 phosphorylation of AS160; (E) and 
expression level of glucose transporter (GLUT4 and GLUT1) in whole-cell lysates were 
determined. Fully differentiated 3T3-L1 adipocytes were incubated in serum-free DMEM 
overnight then treated with 10 µg/mL oligomycin and 5 µM celastrol for 48 h. Insulin  
(10 μg/mL) was added into plate for 30 min at 37 °C. β-actin was used as loading control. 
Protein levels measured were normalized against β-actin. * p < 0.05 vs. untreated control;  
# p< 0.05 vs. basal rate; + p < 0.05 vs. oligomycin-treated cells. 
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2.8. Discussion 
In recent years, emerging evidence has been gathered to support the notion that an increase of 
oxidative stress, mitochondrial damage and exacerbated inflammation are among the key features of 
obesity and type 2 diabetes [1,2,4]. The concerted actions of both acute and chronic inflammation with 
augmented superoxide free radicals productions can lead to further reduce the ATP generation, 
consequently impeding insulin-signaling activities in a number of peripheral tissues. Although it is 
broadly appreciated that oxidative stress and inflammation lead to development of insulin resistance, the 
therapeutic interventions in modulating these mitochondrial dysfunction-induced inflammations are 
relatively scarce. Therefore, further research in orchestrating other regulatory mechanisms and its 
ameliorative properties may provide an insight towards effective treatments of such disorders. Activation 
of redox-sensitive inflammatory pathways via NF-κB signaling by mitochondrial dysfunction has been 
postulated as an adaptive system of cellular stress towards overwhelmed generation of ROS [21].  
One study has reported that the involvement of NF-κB pathways inhibits adipogenesis in murine cells [28] 
whereas the expression of adipocyte-specific genes were down-regulated by pre-treatment with  
TNF-α via NF-κB pathways [29]. Nevertheless, the precise mechanism linking NF-κB activation and 
mitochondrial dysfunction in adipocytes are still rather ambiguous. 
Following the recent correlation between mitochondrial dysfunction and inflammation, the present 
study envisaged to further determine the mechanistic effect of a major regulator inflammatory response 
drug, celastrol upon treatment of common mitochondrial respiratory enzyme inhibitors oligomycin on 
fully differentiated 3T3-L1 adipocytes. We established an in vitro model of mitochondrial dysfunction 
in adipocytes through impairment of ATP synthase by 10 μM oligomycin treatment for 48 h. In parallel,  
to discover the involvement of NF-κB signaling pathways activation, we co-incubated oligomycin-treated 
cells with 5 μM celastrol for 48 h. The dose response and time course of the cell viability were performed 
accordingly in order to avoid possible toxic effects of oligomycin and celastrol (Figure 1C,D). After 
treatment with oligomycin, we confirmed earlier findings that mitochondrial dysfunction directly affects 
oxidative metabolism of adipocytes in the absence and presence of insulin [30,31]. Furthermore, with the  
use of this in vitro model, we observed a marked improvement of metabolic functions of 3T3-L1 
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adipocytes with mitochondrial dysfunction after treatment with celastrol. Our data in this study are the 
first to implicate the role of NF-κB inhibition in a mechanism of insulin resistance in adipocytes induced 
by mitochondrial dysfunction. 
Studies have recently demonstrated an association of mitochondrial dysfunction in adipocytes  
of subjects with a positive family history of diabetes, and in animals with obesity-associated  
type 2 diabetes [32,33]. Accordingly, uncontrolled generation of ROS in the event of mitochondrial 
dysfunction in other cell types have been linked to the stimulation of inflammatory signaling pathways 
via NF-κB activation [22]. Low-grade inflammatory and matrix degradation responses via mitochondrial 
Ca2+ exchange, ROS generation, and NF-κB activation may also contribute to the development of 
mitochondrial dysfunction [20]. The induction of mitochondrial dysfunction via inhibition of 
mitochondrial ATP synthase, oligomycin, significantly potentiates the cytokine-induced inflammatory 
response in normal synovial fibroblasts with an increase of PGE2 and IL-8 release. The authors evidenced 
that this inflammatory mechanism is regulated via ROS production and NF-κB activation [34]. In other cell 
types, the impairment of mitochondrial functions was also resulted in over-production of ROS, leading 
to the cytotoxicity progression with an accumulated inflammatory cytokines [35]. Consistent with these 
findings, a recent study utilizing integrative approach combining in vivo and in vitro revealed that an 
augmented expression of inflammatory genes is implicated in the enhanced sensitivity of NF-κB binding 
site to the promoter region of the cell in the context of mitochondrial dysfunction [22,36]. Similarly, 
with regard to the latter possibility in the mechanism of mitochondrial dysfunction, we have determined 
the effects of celastrol on differentiated 3T3-L1 adipocytes treated with oligomycin. A significant 
enrichment of intracellular ATP concentration with reduced ROS production was observed. In addition, 
an elevated mitochondrial membrane potential was detected in the celastrol-treated cells with 
oligomycin, suggesting the involvement of NF-κB signaling pathways in modulating such metabolic 
perturbations (Figure 2A–C). 
As reduced mitochondrial functions with altered morphology are associated with mitochondrial 
dynamics, we next investigated the effects of celastrol on the expression of proteins responsible for 
mitochondrial fusion and fission. Mitochondria are dynamic organelles that frequently undergo fusion 
and fission in order to exchange power and content. The aberrant mitochondrial function indicates  
an imbalance of the cellular bioenergetics affecting mitochondrial fusion and fission. Mfn1 and Mfn2 
are the key enzymes that involve in mitochondrial fusion via GTPase activity [37] while Drp1 is the 
main target protein participates in the mitochondrial fission in regards to mitochondrial division, stress 
response and apoptosis [38]. At present, the protein levels of Mfn1 and Drp1 were up-regulated in the 
events of mitochondrial dysfunctions of adipocytes while mfn2 protein level remained unchanged after 
treatment with oligomycin (Figure 3A–C). Gao and colleagues observed that the metabolic expression 
of Mfn1 and Drp1 in 3T3-L1 adipocytes was greatly altered in the high glucose and high free fatty acids 
while the level of Mfn2 was unaltered after all treatments [16]. Later, the same group also identified 
treatment with TNF-α on 3T3-L1 adipocytes affects mitochondrial dynamics of Mfn2 and Drp1 level 
whereas the expression of Mfn1 protein level was not affected [15]. The differences of the findings in 
both studies were not fully elucidated, as the metabolic regulation of mitochondrial fusion and fission 
are too complex to be understood. The authors believed that the changes in mitochondrial fusion and 
fission here are still worthy of further detailed investigation. Recently, another report [39] suggested that 
enforced mitochondrial hyperfusion by expressing a dominant-negative mutant of Drp1 or of MARCH5 
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resulted in the activation of NF-κB inflammatory signaling pathways in an activated kinase-1 (TAK1) 
and IKK-dependent manner, through the mitochondrial E3 ubiquitin ligase activator of NF-κB 
(MULAN). The study has concluded that mitochondria through mitochondrial fusion and fission convert 
the stress signal into cellular response via activation of NF-κB pathways [39]. This is consistent with our 
result on identifying the roles of NF-κB activation in mitochondrial dynamics of adipocytes with 
mitochondrial dysfunction. We observed that co-incubation of celastrol in oligomycin-treated cells 
significantly increased and reduced the expression of Mfn1 and Drp1 protein level, respectively, while 
expression of mfn2 was unaffected (Figure 3A–C). 
It is of paramount importance to understand that emerging studies have started to propose the 
inflammatory signaling pathways mediated by activation of IKK-β/NF-κB pathways and other 
transcription factors are the central arbitrator in understanding oxidative stress responses in  
obesity-related conditions [6]. In view of that, a report utilizing obese db/db mice found that enhanced 
NF-κB activity was coupled with intensified oxidative stress as demonstrated by abnormal accumulation 
of mitochondrial superoxide productions [40]. Likewise, this complex interaction is also evidenced by 
our data showing that NF-κB inhibitor significantly improved the oxidative metabolism of adipocytes 
treated with ATP synthase inhibitor through a reduced oxidative stress in adipocytes with mitochondrial 
dysfunction. The accumulation of cellular DNA damage either from nucleus and mitochondria is thought 
to contribute to aging process mediated via changes in redox status and oxidative stress-induced 
inflammatory responses [41]. Several studies have revealed that diminished mitochondrial oxidative 
phosphorylation and ATP production following mtDNA damage, and oxidative stress are collectively 
contribute to the co-regulation of NF-κB and inflammasome-mediated inflammatory responses 
activation, precede the development of type-2 diabetes mellitus [42–44]. The involvements of advanced 
glycation end (AGE) products may also affect the redox status of inflammatory signaling pathways. 
Treatment with glycolaldehyde-derived AGE3 on human aortic endothelial cells results in the elevated 
8-OHdG formation and TNF-α concentration. The authors also observed that an inhibition of NF-κB 
activation suppressed AGE3-induced 8-OHdG formation, implying that sustained activation of NF-κB might 
be play pivotal roles for endothelial dysfunction in diabetes [45]. 
Carbonylation is a type of protein oxidation involving non-reversible direct oxidation of the side 
chains of cysteine, histidine, and lysine residues by lipid peroxidation end products such as 4-hydroxy 
and 4-oxononenal [46]. An elevation of protein carbonylation is observed in the subcutaneous human 
adipose tissue [47] and adipose tissue of diet-induced obese mice [48]. The upsurge of protein 
carbonylation level was revealed to play a major instigating role in the inflammation related pathways. 
Chronic treatment of 3T3-L1 adipocytes with pro-inflammatory cytokines TNF-α lead to development 
of mitochondrial dysfunction, protein carbonylation and lipid peroxidation [48]. This is supported by 
another observation showing the oxidation of thioredoxin (a class of small redox proteins) that result in 
the release and activation of apoptosis signal-regulating kinase 1 (ASK1) have been linked to progression 
of mitochondrial dysfunction-induced inflammation. This process initiate a cascade of phosphorylation 
events culminating in the activation of c-Jun N-terminal kinases (c-JNKs) and the NF-κB pathway as 
well as serine phosphorylation of IRS1, giving rise to the formation of oxidized lipid and proteins [49]. 
Lipid peroxidation is an activated metabolic process that signals the redox imbalance causes  
the activation of intracellular inflammatory signaling pathways. 4-hydroxy-trans-2-nonenal (HNE), 
malondialdehyde and acrolein are among the common by-products of lipid peroxidation that were shown 
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to activate various signaling intermediates and regulate cellular dysfunctions involving redox-sensitive 
transcription factor NF-κB [50]. A study utilizing Male Sprague-Dawley rats has shown that inhibition 
of lipid peroxidation by administration of raxofelast results in a significant reduction of MDA and 
declined myeloperoxidase (MPO) activity through suppression of pancreatic NF-κB activation and the 
TNF-α mRNA levels [51]. Moreover, another study signified that the activation of a redox-sensitive 
transcription factor NF-κB signaling pathways in the event of lipid peroxidation lead to the 
posttranslational modification of proteins and DNA leading to cytotoxicity and genotoxicity [50].  
These observations were in parallel with our data showing that amplified level of DNA oxidative damage, 
protein carbonylation and lipid peroxidation was observed in the oligomycin-treated cell but inhibited by 
celastrol treatment for 48 h (Figure 4A). These evidences indicated that celastrol is a potent inhibitor of 
oxidative stress-induced activation of NF-κB in 3T3-L1 adipocytes. 
Inadequate suppression of lipolysis in adipose tissues and boosted delivery of free fatty acids into 
ectopic tissues (e.g., muscle, pancreas and liver) play a key role in the exacerbation of insulin resistance [2]. 
Several pro-inflammatory cytokines has been shown to induce enhanced lipolysis in adipocytes.  
Co-treatment of 3T3-L1 adipocytes with IL-6 lead to augmented lipolysis with diminished ATP  
content [52]. The stimulatory effects of TNF-α on the cellular lipolysis was also documented via the 
mitogen-activated protein kinase (MAPK) family involving extracellular signal-related kinase (ERK) 
and JNK in different type of cells [53]. Incubation of primary cultures of human adipocytes in the 
presence of a cell-permeable peptide that inhibits NF-κB signaling showed the abolishment of  
the nuclear translocation of NF-κB in the event of TNF-α-induced lipolysis [54]. Our data contributes  
to a new finding that an intensification of lipolysis through the impairment of adipocyte ATP synthase 
may be regulated by the activation of NF-κB signaling pathways (Figure 5A,B). 
Furthermore, the data presented in this study also demonstrated that suppression of IKK-β/NF-κB 
signaling pathway by celastrol may also give rise to the diminished intracellular accumulation of lipid 
droplets in 3T3-L1 adipocytes treated with oligomycin (Figure 5C–G). Abnormal lipid deposition in 
various peripheral tissues has been proposed as one of detrimental occasions in the progression of obesity 
and insulin resistance-related diseases [3]. In normal physiological conditions, the relative levels of fatty 
acids are constantly maintained at the balance of utilization and deposition. Abnormal accumulation of 
lipids due to enlarged adipocytes mass resulted in a disproportionate rate of fatty acid oxidation, causing 
the cellular deposition of various lengths of acylcarnitine fatty acids. The incomplete fatty acid oxidation in 
mitochondria is prominent to be observed as the efficiency of mitochondrial functions was blunted. It is 
not surprising that treatment of adipocytes with oligomycin may result in excess intracellular lipid 
accumulations due to aberrant mitochondrial functions to metabolize these lipid intermediates. The 
dysfunctional lipid storage in adipocytes are significantly correlated to the downstream effects of TLR4 
stimulation via activation of NF-κB transcription factor, which then triggers the transcription of many 
pro-inflammatory genes [55]. 
Adipose tissue is now appreciated as one of the important endocrine tissues that secrete hormones 
and circulating cytokines such as TNF-α and IL-1β. The relative level of these pro-inflammatory 
cytokines were elevated in obese and diabetic people [14]. High levels of recombinant TNF-α and  
IL-1β in co-cultured 3T3-L1 adipocytes with primary peritoneal mouse macrophages were identified to 
inhibit the expression of GLUT4 in 3T3-L1 adipocytes [56]. Notably, excessive production of  
pro-inflammatory cytokines is characterized by defective mitochondrial functions, oxidative stress with 
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over-generation of ROS [7]. Moreover, the activation of transcription factor NF-κB was proved to be a 
target of oxidative stress. Direct exposure of H2O2 in certain cell types was shown to be an effective 
inducer of NF-κB activation [57]. The linkage of oxidative stress and NF-κB activation are connected to 
the elevated production of pro-inflammatory cytokines that lead to inhibition of intracellular insulin 
signaling activities in a number of peripheral tissues [5]. These data suggest that elevated pro-inflammatory 
cytokines are strongly connected to the onset of oxidative stress induced insulin resistance. Our study 
showed that the concentration of IL-1β and TNF-α was higher in adipocytes with mitochondrial 
dysfunction than untreated cells. The pharmacologic modulation of NF-κB activation with celastrol 
significantly prevented up-regulation of TNF-α and IL-1β level in oligomycin-treated cells, supporting 
the previous findings that NF-κB regulate the enhanced expression of IL-1β and TNF-α correlated with 
mitochondrial dysfunction [1]. These results have at least provided solid evidence to substantiate that 
inhibition of IKK-β/NF-κB inflammatory signaling pathways play a role in modulating mitochondrial 
dysfunction-induced insulin resistance in 3T3-L1 adipocytes with inflammation (Figure 6A,B). 
On the other hand, the attenuation effects of adipocytes with mitochondrial dysfunction by celastrol 
in this study are not limited to the abovementioned findings, but also significantly implicated in the 
restoration of insulin induced-glucose uptake and enhanced insulin-signaling activity (Figure 7A–D).  
It has been established that adipose tissues with mitochondrial dysfunction that occurs in the metabolic 
syndrome are manifested with impaired glucose homeostasis and insulin insensitivity [32,34].  
The progressive enlargement of adipocytes mass with an infiltration of macrophage may lead to  
the over-production of pro-inflammatory cytokines with hypoxia-induced a decline in glucose utilization 
rate [58]. Multiple in vitro studies revealed that impaired glucose homeostasis relatively results from 
reduced mitochondrial functions. Co-treatment of 3T3-L1 adipocytes with high concentration of glucose 
and free fatty acids was shown to stimulate mitochondrial dysfunction [16]. In addition, a significant 
decrease in insulin-stimulated glucose uptake was observed in 3T3-L1 adipocytes with mitochondrial 
dysfunctions after four days exposure of pro-inflammatory cytokine TNF-α [15]. Another group showed 
that [31] the induction of mitochondrial dysfunction and over-production of ROS in adipocytes by 
adding mitochondrial inhibitors and knockdown of mitochondrial transcription factor A (mtTFA), 
respectively result in the lowered glucose uptake and impaired insulin signaling activity upon insulin 
stimulation in adipocytes. They also noticed that the expression of GLUT4 and secretion of adiponectin 
was significantly blunted in adipocytes with mitochondrial dysfunctions. Mauro and colleagues have 
proposed that an activation of NF-κB may affects the cellular reprogramming of bioenergetics pathways 
involving mitochondrial respiration and glucose utilization [59]. Our results first illustrated that 
inhibition of NF-κB pathways by incubating celastrol in 3T3-L1 adipocytes with mitochondrial 
dysfunction improved glucose uptake activity. Enhanced insulin signaling pathways were significantly 
observed via boosted phosphorylation of Tyr612 residue of IRS1, Ser473 residue of Akt/PKB, Thr642 
residue of AS160 (Figure 7A–D), possibly implying this inflammatory signaling pathway is implicated 
in the pathogenesis of insulin resistance in adipose tissue with mitochondrial dysfunction. 
The relative translocation of glucose transporter over the plasma membrane from intracellular storage 
vesicles within insulin-sensitive tissues is a major regulatory process for the maintenance of blood 
glucose homeostasis. GLUT4, also called the “insulin-regulated glucose transporter”, is one of the  
key proteins involved in the glucose uptake activity relative to insulin stimulation through an  
ATP-independent, facilitative diffusion mechanism. High expression of this membrane protein was 
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evidenced in adipose tissues and skeletal muscle [60]. Particularly, reduced expression level of GLUT4 
is associated with the pathogenesis of type 2 diabetes where transgenic mice with severe alteration of 
GLUT4 level developed insulin resistance with impaired glucose homeostasis [61]. Our result revealed 
that an inhibition of ATP synthase in adipocytes was led to a significant depletion of GLUT4 level 
(Figure 7E). Concurrent increase of ROS production has been suggested as one of the metabolic insults 
that down-regulate the expression of GLUT4 level upon oligomycin treatment [31]. Oxidative stress 
elicited by mitochondrial dysfunction may contribute to the insulin insensitivity of adipocytes.  
Co-incubation with celastrol on 3T3-L1 adipocytes with mitochondrial dysfunction significantly 
abrogated the effect of oligomycin on GLUT4 protein expression in 3T3-L1 adipocytes (Figure 7E). 
Therefore, it can be exemplified that the amelioration properties possess by celastrol on the inhibition of 
NF-κB pathways are correlated with the translocation of GLUT4. Our study is in agreement with another 
report utilizing streptozotocin-induced diabetic Sprague-Dawley rats by specifying that the inhibition of 
NF-κB activity elevates the expression of GLUT4 in uterus of diabetic rats [62], indicating the roles of 
NF-κB may be allied with the relative expression of GLUT-4. 
GLUT1 is another type of membrane protein in glucose transporter family that ubiquitously express 
for indicating basal glucose uptake. The stimulation of AMP-activated protein kinase (AMPK) is 
reportedly coupled to the enhancement of GLUT1-mediated glucose transport [63]. Furthermore, 
activation of ERK also leads to the up-regulated expression of GLUT1, resulting in the elevation of basal 
glucose uptake in the absence of insulin stimulation. Presently, we found no significant changes on the 
GLUT1 protein level neither in the oligomycin treated cell nor with co-treatment of celastrol. Our data 
is consistent with the study done by Wang et al. [31]. We believe that the mechanism behind this 
observation is due to intrinsic function of GLUT1 to compensate the maintenance of relative basal 
glucose uptake in the cell. It was reported that an enhancement of GLUT1 protein level was observed in 
human cells with mitochondrial dysfunction [64]. Our result indicated that the expression of this protein 
level was unchanged, specifying that GLUT1 was not involved in NF-κB pathways of adipocytes with 
mitochondrial dysfunction (Figure 7E).  
The primary goal of our work is to investigate the in-vitro mechanism of NF-κB inhibition in  
the development of mitochondrial dysfunction induced insulin resistance in differentiated 3T3-L1 
adipocytes. The limitation of the present study is the use of in-vitro adipocytes to study the effects of 
NF-κB pathway inhibition in adipocytes with mitochondrial dysfunction. It is clear from our own 
understanding that further in vivo study utilizing genetically modified cells (knockout, over or  
down-regulation of the NF-κB gene) will better characterize the roles of NF-κB pathways in the 
development of mitochondrial dysfunction-induced insulin resistance. However, we believe that our 
works have much value of expositing the specific mechanistic interaction of this regulatory pathway in 
the development of such perturbations. We hope that this study will be an important reference for 
therapeutic intervention of diabetes, especially for those diabetes patients with inflammatory disease. 
Further experimental methodologies in systems-based approaches should be continued to explore the 
underlying mechanisms of such impairments. The systemic interaction involving whole body 
homeostasis may represent the holistic assessment of disease mechanisms from the metabolic 
understanding point of views [65]. 
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3. Experimental Section 
3.1. Cell Culture 
3T3-L1 pre-adipocytes were purchased from the American Type Culture Collection (ATCC) 
(Manassas, VA, USA) and grown in Dulbecco’s Modified Eagle Medium (DMEM) with high glucose 
(Gibco, Carlsbad, CA, USA) supplemented with 10% of fetal calf serum (FCS) and 1% of penicillin, 
streptomycin (antibiotics) (Gibco). The cells were sub-cultured every three days before the culture 
becomes fully confluent, which are about 70%–80% of sub-confluent culture. The standard seeding 
density used was 2 × 105–4 × 105 cells/cm2 and seeded in a 75 cm2 flask followed by incubated at 37 °C 
in the humidified atmosphere of 5% CO2. The 3T3-L1 pre-adipocytes were differentiated into adipocytes 
using a standard protocol [66]. Briefly, the cells were incubated for 48 h before undergo full 
differentiation. Later, cells were maintained in regular growth medium supplemented with adipogenic 
cocktail containing MDI (0.5 mM 3-isobutyl-1-methyl-xanthine (IBMX), 0.25 μM dexamethasone and 
1 μg/mL insulin) (Sigma, St. Louis, MO, USA) for 2 days. On the 4th day, the media was replaced for 
every two days with DMEM containing 10% fetal bovine serum (FBS) till 8th day of adipocytes 
differentiation. In differentiated adipocytes, certain experiments involved stimulation with insulin  
(10 μg/mL) for 30 min at 37 °C. To avoid confounding variables, the protocol used for insulin stimulation 
was similar to all types of experiments involving insulin-signaling activities in order. The insulin 
stimulation is necessary to 3T3-L1 adipocytes in order to measure the glucose uptake and its metabolic 
activities relative basal level. As insulin resistance is associated with reduced glucose uptake and 
deteriorated insulin-signaling activities, the experimental approach with insulin stimulation is crucial to 
observe the underlying effects of such inhibitors on 3T3-L1 adipocytes. According to the standard 
protocol used widely for treating 3T3-L1 adipocytes, pharmacological level of insulin (10 μg/mL) induce 
mitosis in adipocytes and 30 min treatment prior to any assays would be useful to observe the effects  
on insulin-signaling activities [67]. Therefore, insulin dose of 10 µg/mL was chosen for all experiments 
involving insulin stimulation effects. 
3.2. Oligomycin and Celastrol Treatment 
The establishment of mitochondrial dysfunction-mediated insulin resistance in 3T3-L1 adipocytes 
was performed as previously described [30]. On the 8th day after induction, fully differentiated  
3T3-L1 adipocytes were serum starved for 18 h. The goal of serum starvation is to synchronize the cell 
cycle. The cells were serum starved before the treatment was performed. Then, the cell-based assays 
were performed accordingly. Oligomycin (Sigma), ATP synthase inhibitor was used to induce 
mitochondrial dysfunction in adipocytes. Cells were treated with oligomycin with or without celastrol 
(Sigma). The cells without treatment were used as controls. Media in control and treated cells were 
replaced daily, and assays were executed after 9th or 10th day of post-differentiations. 
3.3. Measurement of Cell Viability 
Cell viability was assessed by MTT assay. 3T3-L1 adipocytes were grown in 96-well plates. Cells were 
then incubated with varying concentration of oligomycin (5, 10, 20 and 30 µM) with or without celastrol 
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(5, 10, 20 and 30 μM) in DMSO. Our preliminary study revealed that the use of DMSO in growth media 
did not affect the cell viability of adipocytes differentiation at a final concentration of 0.1% (data not shown). 
To ensure the integrity of adipocytes functions, the optimal dose for each inhibitor that did not 
significantly affect cell viability was chosen for time-course evaluation. The time-course dependent was 
evaluated for each optimal dose (12, 24, 36 and 48 h). Briefly, phosphate buffer saline (PBS) was used 
to dissolve 5 mg/mL MTT before filtered through 0.2 μM micro-filter and will be stored at 4 °C.  
Fully differentiated 3T3-L1 adipocytes were washed out with PBS. 10 μL of MTT stock solution was 
prepared and subsequently added into each well and incubated for 3–4 h at 37 °C. After that, 200 μL of 
dimethyl sulfoxide (DMSO) was transferred into each well to dissolve the insoluble purple formazan 
product into coloured solution. The absorbance of the colored solution was measured at the wavelength 
of 570 nm and reference wavelength of 630 nm using the ELISA plate reader (Erba LisaScan II, 
Mannheim, Germany). Optical densities of treated cells were normalized to controls. Each condition was 
performed in triplicate. 
3.4. Intracellular ATP Concentration 
Intracellular ATP concentrations were assayed by using a calorimetric ATP Assay Kit (KA0806; 
Abnova Corporation, Walnut, CA, USA). The cells were lysed in 100 μL ATP Assay Buffer followed 
by deproteinization of cell lysates using 10 kDa Spin Column. Using ATP standard, intracellular ATP 
concentrations were then determined with ELISA plate reader measured at the wavelength of 570 nm 
and normalized to protein concentrations. 
3.5. Measurement of Mitochondrial Membrane Potentials (ΔΨm) 
The measurement of mitochondrial membrane potential were determined using the mitochondria-specific 
lipophilic cationic fluorescence dye 5,5',6,6'-tetrachloro-1,1',3,3'-tetraethylbenzimi-dazolylcarbocyanine 
iodide (JC-1) Detection Kit (KA1324; Abnova Corporation) following the manufacturer’s instruction. 
Briefly, treated 1 × 106 cells were plated on 96-well black culture plate in 100 μL culture medium in a 
CO2 incubator overnight at 37 °C. After then, 10 μL of the JC-1 Staining Solution were added to each 
well and incubated in CO2 incubator at 37 °C for 15–30 min. The plate was centrifuged for 5 min at 
400× g at room temperature and supernatant was discarded. 100 μL of Assay Buffer was added to each 
well and ready for analysis by a fluorescent plate reader (Promega, Madison, WI, USA). J-aggregates 
were formed in healthy cells with excitation and emission at 560 and 595 nm, respectively. In unhealthy 
cells, JC-1 exists as monomers that was excited at 485 nm and emits at 535 nm. 
3.6. Mitochondrial Superoxide Measurement 
Cells in black-walled 96-well plates were treated with oligomycin and celastrol for 48 h as described 
above. ROS production in adipocytes was measured by incubating cells with 1 µM Mitosox Red 
(Invitrogen Molecular Probes, Carlsbad, CA, USA) for 30 min at 37 °C. After two times washes with 
PBS, cells were collected and used for fluorescence analysis using a multimode plate reader at an 
excitation wavelength of 510 nm and an emission wavelength of 580 nm. 
  




Western blotting analysis was carried out as previously described [68]. Briefly, after treatments,  
the cells were washed twice with Krebs-Ringer HEPES buffer and homogenized with protein lysis buffer 
(50 mM Tris pH 7.5, 1 mM EDTA, 1 mM EGTA, 10% glycerol, 1% triton X-100, 50 mM NaF, 5 mM 
Na4P2O7, 1 mM Na3VO4, 1 mM DTT) containing protease and phosphatase inhibitors. The cell lysate 
was incubated on ice for about 1 h with constant mixing. Proteins concentrations were quantified using 
a Pierce™ BCA Protein Assay Kit (Thermo Scientific, Waltham, MA, USA). To be used as a whole 
protein, supernatants were collected after centrifugation at 16,000× g for 20 min at 4 °C. The aliquots of 
whole protein was separated on odecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), and 
transferred to nitrocellulose membranes (Whatman, London, UK). Membrane were blocked with  
Tris-buffered saline/Tween-20 (TBST, 0.14 mol/L NaCl, 0.02 mol/L Tris base (pH 7.6), and 0.1% Tween) 
containing 5% w/v bovine serum albumin (BSA) for 1 h at room temperature. After then, the membranes 
were incubated overnight at 4 °C with specific primary antibodies of interest, at the dilution indicated, 
in TBST: NF-κB p65 (1:1000, Cell Signaling Technology, Danvers, MA, USA), mfn1 (1:1000,  
Santa Cruz Biotechnology, Santa Cruz, CA, USA), mfn2 (1:1000, Santa Cruz Biotechnology), drp1 
(1:1000, Santa Cruz Biotechnology), pY612-IRS1 (1:1000, Upstate Biotechnology, Lake Placid, New 
York, NY, USA), IRS1 (1:1000, Upstate), pS473-Akt (1:1000, Cell Signaling Technology), Akt (1:1000, 
Cell Signaling Technology), pS462 AS160 (1:1000, Cell Signaling Technology), AS160 (1:1000, Cell 
Signaling Technology), GLUT4 (1:1000, Cell Signaling Technology), GLUT1 (1:1000, Novus 
Biologicals, Littleton, CO, USA) and β-actin (1:1000, Cell Signaling Technology) at room temperature. 
Membranes were washed with TBST at a dilution of 1: 10,000 for 1 h at room temperature before the 
corresponding horseradish peroxidase (HRP)-conjugated secondary antibodies (Pierce Biotechnology, 
Rockford, IL, USA) were treated. Specific immune complexes were detected by chemiluminescence 
using ECL plus kits (Amersham, Piscataway, NJ, USA), visualized using ChemiDoc™ XRS+ (Bio-Rad, 
Hercules, CA, USA) with Image Lab™ software (Bio-Rad, Hercules, CA, USA) and quantified by using 
a standard densitometry. 
3.8. Measurement of DNA Oxidative Damage and Lipid Peroxidation 
8-OHdG is a ubiquitous marker of oxidative stress-mediated DNA damage, was quantified using the 
OxiSelect™ Oxidative DNA Damage ELISA Kit (Cell Biolabs, San Diego, CA, USA) as previously 
described [69]. The lipid peroxidation was assessed by measuring malondialdehyde (MDA) as an end 
product of lipid peroxidation using Lipid Peroxidation (MDA) Assay Kit (Sigma) according to the 
manufacturer’s protocols. 
3.9. Protein Carbonylation 
Protein carbonyls were detected using Protein Carbonyl Content Assay Kit (Cayman, Ann Arbor, MI, 
USA). Briefly, cells were washed with PBS and centrifuged to 1000–2000× g for 10 min at 4 °C. The cell 
pellet was sonicated on ice in 2 mL of cold buffer containing 50 mM phosphate, pH 6.7 with 1 mM 
EDTA. Then, the mixture was centrifuged again at 10,000× g for 15 min at 4 °C and supernatant was 
removed and stored on ice. After that, 800 µL of DPNH and 2.5 M HCI was added to sample and control 
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tubes, respectively. The tubes were incubated for 1 h at dark room temperature followed by the addition 
of 1 mL of 20% TCA to each tube on ice. All tubes were centrifuged at 10,000× g for 10 min at 4 °C 
and supernatant was discarded. The cell pellet was re-suspended in 1 mL of (1:1) ethanol/ethyl acetate 
mixture. These steps were repeated three times in order to remove cellular debris. After the final wash, 
the protein pellet was re-suspended in 500 µL of guanidine hydrochloride and centrifuged at the same 
speed as stated above to remove any leftover debris. Each 220 µL of sample and control tubes were 
transferred to 96-well plates and measured at the absorbance of 385 nm using a plate reader. 
3.10. Measurement of Lipolysis 
Lipolysis was evaluated by measuring the amount of glycerol and free fatty acids released into the 
media. In brief, lipolysis was evaluated by measuring the amount of glycerol and free fatty acids released 
to the media. Glycerol level was determined after 48 h of oligomycin and celastrol treatments while free 
fatty acids release were quantified after 3 h of drugs treatment by using the Lipolysis Assay Kit for Free 
Fatty Acids and Glycerol Detection (Zen-Bio Inc, Research Triangle Park, NC, USA) according to the 
manufacturer’s instructions. 
3.11. Quantification of Lipid Contents by Oil Red O Assay 
Intracellular accumulations of lipid droplets were determined by oil red O staining. This assay was 
performed as previously mentioned [66]. Briefly, 0.7 g of oil red O was dissolved in 200 mL of 
isopropanol and filtered with 0.2 µm. The solution was diluted into a ratio of 6:4 with distilled water. 
The solution was then mixed and allowed to stand for 20 min at room temperature. The cells were  
washed with 10% formalin in PBS and stained with a filtered staining solution for 10 min at 37 °C.  
The stained cells were washed again three times with distilled water and observed under inverted 
fluorescence microscope (Carl Zeiss, Göttingen, Germany) equipped with the digital camera AxioCam 
MRc (Carl Zeiss) for morphological study. For quantification of lipid content, the oil red O was eluted 
by adding 100% isopropanol and incubated for 10 min before measuring the absorbance (OD) at 490 nm 
using ELISA plate reader. 
3.12. Cytokine ELISA for TNF-α and IL-1β Measurement 
The concentrations of pro-inflammatory cytokines TNF-α and IL-1β in the harvested medium  
from adipocytes were measured using a commercially available enzyme-linked immunosorbent assay 
(ELISA) kit (Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s protocol. The minimum 
detectable doses were 7 pg/mL for IL-1β and 3 pg/mL for TNF-α. Each concentration was obtained from 
the standard curve and expressed as per mg of total extractable cell protein. 
3.13. Glucose Uptake Assay 
To evaluate increased dependence on glycolytic metabolism in the presence of mitochondrial 
inhibitors, glucose uptake activity was performed by quantifying the uptake of radio-labelled glucose. 
Briefly, the differentiated cells with and without treatment were grown in 12-well plates and washed 
twice with serum-free media and incubated for 3 h at 37 °C. The cells were washed three times with 
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Krebs-Ringer HEPES (KRPH) buffer and undergo incubation with 0.9 mL of KRPH buffer for  
30 min at 37 °C. The activity of glucose uptake was quantified by the addition of 0.1 mL of KRPH buffer 
comprising 2-deoxy-D-[3H] glucose (0.037 MBq; Perkin Elmer, Foster City, CA, USA) and glucose 
(0.001 mM). The glucose uptake activity was terminated right after 60 min, through washing the cells 
three times with ice-cold PBS. The cells were lysed through incubation for 20 min at 37 °C with 0.7 mL 
of 1% Triton X-100. The radioactivity level in the cell lysates were quantified by using Tri-Carb 2700TR 
liquid scintillation counter. 
3.14. Statistical Analysis 
Experimental results were shown as the mean means ± standard error of the mean (SEM) of the 
indicated sample size (n). Statistical significance of data was determined using paired and unpaired 
Student’s t-test. One-way ANOVA with Tukey post-hoc was utilized where more than two groups were 
compared with treatments. A value of p < 0.05 was considered as statistically significant. 
4. Conclusions 
In summary, based on the results obtained in this study, we have proposed additional support to the 
hypothesis that a decline in mitochondrial function is significantly associated with differentiated  
3T3-L1 adipocytes inflammatory phenotype observed in insulin resistance-associated diseases. The 
results of the present study verify that mitochondrial dysfunction alone may disturb oxidative 
metabolism and promotes low-grade inflammation in adipocytes. These metabolic insults were 
ameliorated by the addition of celastrol on the differentiated adipocytes with mitochondrial dysfunction. 
To our best knowledge, this is the first report demonstrating deterioration of mitochondrial function in 
adipocytes with insulin resistance is correlated with the activation of NF-κB pathways. The limitation of 
the present study is the use of in vitro model of 3T3-L1 adipocytes to observe such effects on the 
ameliorative properties of NF-κB inhibitor. The use of different methodologies in further evaluating NF-κB 
expression activity is imperatively needed. In addition, future analyses involving in vivo and human 
studies should be continued to explicate the role of this inflammatory signaling pathway in these 
metabolic perturbations. However, our results have substantiated the mechanistic role of inflammation 
in the dysregulation of oxidative metabolism in adipose tissues. The study have provided valuable 
information for the development of an envisaged therapeutic strategy in insulin resistance and  
type 2 diabetes. 
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